Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31048874 | 0.81 | VNN1 (0.47) | RIPK1MTNR1AMTNR1BGPR119 | |
| SCHEMBL28301761 | 0.79 | MTNR1A (0.48) | MTNR1AMTNR1BGPR119MIF | |
| SCHEMBL6864273 | 0.77 | CES2 (0.46) | RIPK1P2RX7CA2 | |
| SCHEMBL31552196 | 0.77 | RIPK1 (0.42) | RIPK1MTNR1AMTNR1BMIF | |
| SCHEMBL31551958 | 0.76 | CES2 (0.39) | RIPK1P2RX7CA2 | |
| SCHEMBL6445445 | 0.76 | RIPK1 (0.42) | RIPK1P2RX7CA2DGAT2 | |
| SCHEMBL29181812 | 0.75 | MTNR1A (0.45) | MTNR1AMTNR1BMIF | |
| SCHEMBL23043726 | 0.74 | KDM4E (0.49) | — | |
| SCHEMBL25972038 | 0.74 | MTNR1A (0.49) | RIPK1MTNR1AMTNR1BGPR119 | |
| SCHEMBL3456260 | 0.73 | RIPK1 (0.41) | RIPK1MTNR1AMTNR1BGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250179093-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2025064542-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179093-A1 | KRAS MODULATORS | KRAS, NRAS, HRAS | RIPK1 695/4885MTNR1A 3692/4885MTNR1B 3517/4885 |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | RIPK1 960/4885MTNR1A 3249/4885MTNR1B 2754/4885 |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | RIPK1 2238/4885MTNR1A 183/4885MTNR1B 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.